Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence.

Trial Profile

Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2013

At a glance

  • Drugs Cizolirtine (Primary) ; Tolterodine
  • Indications Urge incontinence
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Esteve
  • Most Recent Events

    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top